The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

The Medscape team is back in Chicago for the much-anticipated ACC 2025 conference,  March 29-31, bringing an array of ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...

JPMorgan upgraded Alnylam (ALNY) to Overweight from Neutral with a price target of $328, up from $280. The firm increased TTR silencer ...

JPMorgan lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $47 and keeps a Neutral rating on the shares. The firm ...

As Arne Slot continues to refine Liverpool’s squad for the future, one area that requires immediate attention is defensive ...

Recent health updates include a rise in measles cases in Texas and New Mexico, expansion of Alnylam's heart disease drug ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat reports. One ...